Clinical Trial Update: Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating vorinostat in combination with gemcitabine, busulfan, and melphalan with stem cell transplantation for relapsed or refractory lymphoid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• Gemzar (gemcitabine)
• Melphalan (Melphalan)
• Zolinza (vorinostat)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 1 | Status: COMPLETED